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F-18 Fluciclovine (AxuminTM) Positron Emission 
Tomography: The New Kid On The Block
David S Lin MD, Ishani Dalal MD
Henry Ford Health System, Detroit, MI
• Prostate cancer is the leading non-skin malignancy in the United States and the 
second most common cause of cancer-related mortality
• Since the advent of prostate specific antigen (PSA) serum testing, most cases of 
prostate cancer are detected while still localized to the prostate gland, enabling 
treatment by surgical prostatectomy and/or radiation therapy
• Following treatment, patients are monitored with PSA testing and although often 
curative, approximately 30% of patients experience a recurrence of their cancer, 
detected as a rising PSA, termed biochemical recurrence
• Prostate cancer recurrence may be classified as local, locoregional, or systemic
– Type of recurrence influences the choice of therapy offered
• Detection of extraprostatic recurrence by conventional imaging is very low, 11% in 
one study, and therefore there is a significant need for more sensitive imaging to 
detect locations of recurrence
Introduction
• The first commercially available FDA-approved prostate specific 
membrane antigen (PSMA) agent is In-111 capromab pendetide
(ProstaScint®)
• New prostate cancer positron emission tomography (PET) agents have 
recently been developed
– F-18 Fluciclovine (AxuminTM)
– Ga-68 PSMA
– C-11 Choline
– C-11 Acetate
– F-18 Choline
Molecular Imaging Agents
• Trade name AxuminTM
• Synthetic amino acid most similar to glutamine, 
an important substrate for tumor metabolism
• Enters cells via amino acid transporters LAT1 and 
ASCT2, which are upregulated in cancer cells, 
most notably prostate cancer
– LAT1 and ASCT2 transporters associated with 
aggressive cancers
• Unlike other amino acids used in metabolic 
imaging, F-18 Fluciclovine is not metabolized or 
incorporated into proteins
F-18 Fluciclovine
• F-18 Fluciclovine studies are most likely to be 
positive with PSA levels >1 ng/mL, however can 
be positive with lower PSA levels
• 82% positive predictive value for tumor 
localization when used in combination with MRI
• Demonstrates utility in further workup in the 
setting of a negative bone scan
• Less sensitive for osseous metastases
• Initial images (<15 minutes) demonstrate most 
intense activity within the pancreas and the liver
• Interpretation is based predominantly on 
qualitative comparison to tissue background
F-18 Fluciclovine
Normal biodistribution
Case 1: 86-year-old male with history of biochemical 
recurrence of prostate cancer. PSA 82 ng/mL.
Maximum intensity 
projection images (left) 
demonstrate multiple 
abnormal foci of increased 
radiotracer uptake
throughout the chest, 
abdomen, and pelvis.
Select axial fused and PET-
only images (right)  
demonstrate multiple foci of 
increased radiotracer uptake 
within the left clavicle, left 
rib, and right acetabulum.  
There is increased radiotracer 
uptake corresponding with an 
enlarged para-aortic lymph 
node. Findings compatible 
with metastatic disease.
Case 2: 57-year-old male with history of biochemical recurrence of prostate 
cancer status post prostatectomy. PSA = 2.7 ng/mL.
Foci of increased radiotracer 
uptake in the right obturator 
region corresponding with 
prominent but nonenlarged
external iliac chain lymph 
nodes.  Findings are 
compatible with metastatic 
disease.
• PSA <1 ng/mL
• Osseous metastases can result in photopenic defects
• Benign prostatic hyperplasia and inflammation (i.e. post 
radiation) can both result in nonmalignant uptake
• Pituitary adenomas, meningiomas, osteoid osteomas, and 
adrenal adenomas can result in focal uptake
• Bladder uptake
• Teratoma
Pitfalls
Case 3: 55-year-old male with history of prostate cancer 
and known osseous metastatic disease. PSA 1.1 ng/mL.
Bone scan (left) demonstrates 
increased radiotracer uptake 
in the right scapula, left 
medial clavicle, bilateral ribs, 
T11 vertebral body, and left 
pelvis.
F18-Fluciclovine PET (right) 
demonstrates a photopenic
defect in the T11 vertebral 
body corresponding to 
diffuse sclerosis in the 
vertebral body and the 
known osseous metastatic 
disease.
• F-18 Fluciclovine is a new and effective PET agent that can be 
used to diagnose local recurrent or distant metastatic disease 
in patients with a history of prostate cancer
• Knowledge of pitfalls as well as potential false positive and 
false negative uptake patterns is crucial for accurate diagnosis 
in these patients
Conclusion
